Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02462954 · ClinicalTrials.gov registry record · Phase 1
A Safety Study Of The Caya® Diaphragm Used With ContraGel®
A Phase 1 study, sponsored by CONRAD.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT02462954 is a Phase 1 study that has completed, run by CONRAD. The registered enrollment target is 23 participants.
The verdict
NCT02462954, a Phase 1 study, has completed, sponsored by CONRAD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety of ContraGel versus the hydroxyethylcellulose (HEC) Universal Placebo gel when used with the Caya diaphragm during two 7-day periods of daily use, the first without intercourse and the second with intercourse.
Interventions
- DEVICE ContraGel
- DEVICE HEC Universal Placebo gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2015-07 |
| Est. Completion | 2016-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02462954
The ClinicalTrials.gov registry entry for NCT02462954 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CONRAD, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ContraGel is the first listed.
NCT02462954 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02462954 about?
NCT02462954 is a clinical study titled "A Safety Study Of The Caya® Diaphragm Used With ContraGel®". The purpose of this study is to evaluate the safety of ContraGel versus the hydroxyethylcellulose (HEC) Universal Placebo gel when used with the Caya diaphragm during two 7-day periods of daily use, the first without intercourse and the second with intercourse.
What is the current status of trial NCT02462954?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2015-07. Estimated completion is 2016-04.
What interventions are being tested in trial NCT02462954?
The interventions under investigation include: ContraGel (DEVICE), HEC Universal Placebo gel (DEVICE).
Who is sponsoring clinical trial NCT02462954?
This trial is sponsored by CONRAD, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.